Is acotinib/cancostat a targeted drug?

Acalabrutinib clearly belongs to the category of targeted drugs. Targeted drugs refer to therapeutic drugs that inhibit tumor cell growth, proliferation or promote apoptosis by specifically acting on a certain molecular target or signaling pathway. The target of acotinib is Bruton's tyrosine kinase (BTK), which plays a central role in B cell receptor signaling and is directly involved in B cell activation, proliferation and survival.

BTK is abnormally active in a variety of B cell malignancies, causing abnormal B cell proliferation and drug resistance. Acotinib inhibits its enzymatic activity by covalently binding to the cysteine u200bu200bresidues of BTK, thus blocking the abnormal activation of downstream signaling pathways. This mechanism allows acotinib to accurately act on tumor cells while having a relatively limited impact on normal cells. Compared with traditional chemotherapy, the incidence of side effects is lower and the safety is more controllable.

In clinical application, acotinib has shown significant efficacy as a targeted drug. Whether used as a monotherapy or in combination with immune drugs such as Otuzumab, it can achieve effective control of patients with mantle cell lymphoma (non-Hodgkin lymphoma), chronic lymphocytic leukemia and small lymphocytic lymphoma by precisely acting on BTK signaling. As a targeted drug, acotinib can not only inhibit tumor cell proliferation, but also reduce disease recurrence rate and prolong patient survival.

Therefore, from the perspective of mechanism of action, target selection and clinical efficacy, acotinib fully meets the definition of a targeted drug. In the field of modern hematological tumor treatment, it is considered a representative drug of the new generation of BTK inhibitors, and also marks that the application of precision therapy in the management of B-cell malignancies has entered a mature stage. In the future, as more clinical research data accumulates, acotinib's targeted treatment strategy may be further optimized to improve efficacy and reduce side effects, providing patients with a safer, long-term management solution.

Reference materials:https://www.calquence.com/